ArticleJournal of family medicine and primary care2025
Decoding the role of serum cholinesterase among type 2 diabetes mellitus patients at RIMS, Ranchi - A hospital-based study.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes mellitus (DM) type 2 is a group of conditions which is defined by persistent hyperglycemia along with various metabolic disturbances in carbohydrate, protein, and lipid metabolism. This condition is characterized by variable levels of insulin resistance, impaired insulin secretion, and elevated glucose production. There are various complications like cardiovascular diseases, neuropathy, nephropathy, and retinopathy which are associated with type 2 DM (T2DM). Serum cholinesterase (ChE) is an alpha glycoprotein enzyme which is formed in the liver and associated with various chronic inflammatory conditions like diabetes, hypertension, and cardiovascular diseases. So, we want to evaluate the correlation between serum cholinesterase concentrations in T2DM and also to evaluate the utility of serum cholinesterase as a diagnostic and prognostic marker in T2DM. Material and Methods: A cross-sectional study was conducted involving 176 participants, divided into two groups: 88 patients diagnosed with T2DM and 88 nondiabetic individuals matched for age and sex who attended at OPD and IPD of Medicine department of RIMS, Ranchi. The height and weight are taken, BMIs are calculated, and blood pressures are recorded. Blood samples are collected from all participants to measure serum cholinesterase levels; FBS, PPBS, HbA1c, serum urea, creatinine, lipid profile, thyroid profile, liver function tests (total bilirubin, direct bilirubin, AST, ALT, alkaline phosphatase), and urine protein creatinine ratio are assessed. Results and Discussion: The activity of serum cholinesterase raised in T2DM compared to the nondiabetic group. The cholinesterase levels in the diabetic group revealed 9272.18 ± 3062.92, median 9661.65, and in nondiabetics, it was 3504.93 ± 1520.74, median 3267.50, with a Conclusion: So, serum cholinesterase concentrations are significantly increased in patients with T2DM and are also associated with poor glycemic control with increased insulin resistance. These study findings demonstrate the potential of serum cholinesterase as a biomarker to monitor the disease progression and its therapeutic effectiveness for interventions in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.